Pharma's Market
SPECIAL REPORT
MOST SHARED
- FTSE, DAX, CAC Seen Lower, Greek Deal Delayed
- India's December Industrial Output Growth Slows Sharply
- Bonus Bloodbath as European Banker Backlash Continues
- Greece Deal Fails to Convince, EU Demands More
- Strip Greenspan of His Knighthood: SocGen Strategist
- Zynga, Hasbro Partner to Make Toys, Games
- Jobs You Can Do Forever
- Citigroup Takes $50 Million Loss in Libor Probe
- New York Fashion Week Hits the Runway as Colors Pop
- Mulling Buffett's Stock Advice? Get in With REITs: Fund Managers
- LinkedIn Earnings Bode Well for Hiring and Social Media
- Top Five Mistakes to Avoid in Online Dating
- Victor Cruz ‘Understands’ Gisele's Super Bowl Frustrations
- Tamminen: The United States of India
- Unusual Volume: Taleo Jumps After Oracle's $1.9 Billion Offer
- Warren Buffett: Stocks Will Outperform Gold and Bonds .. and They're Safer 'By Far'
- So Now You Can’t Give Microsoft Away?
- Citigroup Takes $50 Million Loss in Lending Rate Probe
- Investment Banking Drags Down Barclays Profit
- The Secret Lives of Traders—Seeking the Next Hot Thing
- FBI Investigated Steve Jobs Drug Use
- Strip Greenspan of His Knighthood: SocGen Strategist
- China Imports Slump, Raising Demand Concerns
- Markets Finally Get Greek Deal —So Where's the Rally?
- Warren Buffett: Stocks Will Outperform Gold and Bonds
- Get All the Latest Out of Europe Here
RSS FEED
Amylin's Byetta Battle
Text Size 
Reporter
Of the 36 companies presenting here at the BioCentury/Thomson Reuters biotech conference, investors are probably most interested in the update from Amylin Pharmaceuticals.
The stock has been on a slide since the FDA and the company disclosed a total of six deaths among diabetics who developed pancreatitis after taking Byetta, the twice-a-day injectable drug from AMLN[AMLN
Loading...
()
] and Eli Lilly[LLY
Loading...
()
].
The CFO Mark Foletta did the presentation to the approximately 100 people in the room. CEO Dan Bradbury didn't make it. Foletta went over the facts that I reported on "Fast Money" when the news broke last week--media coverage that he said has "created some confusion in the marketplace."
"While serious," Foletta said, "it's a condition that is rare and is not new. There's no definitive causal relationship between Byetta and pancreatitis, but a possible association is being explored."
Foletta said he thinks the FDA could change the Byetta label regarding the suspected pancreatitis risk around the time it's expected to make a decision on the approval of Byetta for use as a stand-alone treatment for diabetes. That's supposed to happen, Foletta said, by the end of the year.
He also mentioned--and I think this might be new-- that a "major national insurance carrier" informed the company late last week that among the nearly 40,000 patients it has on Byetta there is "no difference" in the incidence of pancreatitis versus diabetics on other drugs.
One observation, though. Foletta didn't acknowledge the elephant in the room--the pancreatitis-related deaths--until around seven minutes into his formal presentation. In the news biz, that's called burying the lead.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes
